Literature DB >> 2473116

Occurrence of mature B (IgM+, B220+) and T (CD3+) lymphocytes in scid mice.

A M Carroll1, R R Hardy, M J Bosma.   

Abstract

Scid mice with and without detectable serum Ig (scid Ig+ and scid Ig- mice, respectively) were examined for the presence of mature "leaky" lymphocytes by flow microfluorimetry with the use of antibodies to B (IgM, B220) and T (CD3, CD4, CD8) lymphocyte surface Ag. The data showed that leaky scid mice are more frequent than is evident from serum Ig analysis and that the incidence of detectable B and T cells increases with age. IgM+ B220+ cells were not detectable in young adult mice (3 mo old), but in old mice (greater than or equal to 1 yr old) they were routinely present in the peritoneal cavity though not in the spleen. Striking differences in the representation of T cell subsets were seen in the thymus of these two age groups. Most young adult mice contained CD3- populations of CD4/CD8 double positive cells, and in some cases, CD4 or CD8 single positive cells as well. By contrast, identifiable T lineage cells in old mice were all CD3+ and predominantly single positive for CD4 or CD8. Detectable peripheral T cell populations numbered less than 10(5) cells, and the representation of T subset markers (CD4, CD8) varied widely among individual mice; further, Southern blot analysis of TCR gene rearrangements in the DNA of polyclonally stimulated lymphoid cultures from these mice showed very restricted heterogeneity relative to that of cultures from normal mice. We conclude that most leaky mice contain very few T cell clones.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2473116

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

1.  Age-dependent increase of peritoneal B-1b B cells in SCID mice.

Authors:  Kirk S Hinkley; Rod J Chiasson; Tracey K Prior; James E Riggs
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

Review 2.  SCID mice in the study of human autoimmune diseases.

Authors:  M A Duchosal
Journal:  Springer Semin Immunopathol       Date:  1992

3.  Restricted heterogeneity of T lymphocytes in combined immunodeficiency with hypereosinophilia (Omenn's syndrome).

Authors:  G de Saint-Basile; F Le Deist; J P de Villartay; N Cerf-Bensussan; O Journet; N Brousse; C Griscelli; A Fischer
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

Review 4.  SCID mice and the study of parasitic disease.

Authors:  K B Seydel; S L Stanley
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

Review 5.  Novel experimental approaches in the study of the immunopathology in inflammatory bowel disease.

Authors:  J Reimann; A Rudolphi; M H Claesson
Journal:  J Mol Med (Berl)       Date:  1995-03       Impact factor: 4.599

6.  Biased T-cell receptor delta element recombination in scid thymocytes.

Authors:  A M Carroll; J K Slack; W T Chang
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

7.  Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent protein kinase catalytic subunit in the scid mouse.

Authors:  T Blunt; D Gell; M Fox; G E Taccioli; A R Lehmann; S P Jackson; P A Jeggo
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

Review 8.  The severe combined immunodeficient (SCID) mouse as a model for the study of autoimmune diseases.

Authors:  A O Vladutiu
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

9.  CD3+ T cells in severe combined immunodeficiency (scid) mice. VI. Rescue of scid-derived, IgM-producing B cells by transfer of CD4+ CD8- T cells from various lymphoid organs.

Authors:  A Rudolphi; M H Claesson; J Reimann
Journal:  Immunology       Date:  1992-10       Impact factor: 7.397

Review 10.  In vivo models of human lymphopoiesis and autoimmunity in severe combined immune deficient mice.

Authors:  T S Barry; B F Haynes
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.